These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23635654)

  • 1. The efficacy of CHK1 inhibitors is not altered by hypoxia, but is enhanced after reoxygenation.
    Hasvold G; Nähse-Kumpf V; Tkacz-Stachowska K; Rofstad EK; Syljuåsen RG
    Mol Cancer Ther; 2013 May; 12(5):705-16. PubMed ID: 23635654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation.
    Hammond EM; Dorie MJ; Giaccia AJ
    Cancer Res; 2004 Sep; 64(18):6556-62. PubMed ID: 15374968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
    Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
    BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
    Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
    Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
    Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
    Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
    Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
    Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
    Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
    Booth L; Cruickshanks N; Ridder T; Dai Y; Grant S; Dent P
    Cancer Biol Ther; 2013 May; 14(5):458-65. PubMed ID: 23917378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure to acute hypoxia induces a transient DNA damage response which includes Chk1 and TLK1.
    Pires IM; Bencokova Z; McGurk C; Hammond EM
    Cell Cycle; 2010 Jul; 9(13):2502-7. PubMed ID: 20581459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
    Landau HJ; McNeely SC; Nair JS; Comenzo RL; Asai T; Friedman H; Jhanwar SC; Nimer SD; Schwartz GK
    Mol Cancer Ther; 2012 Aug; 11(8):1781-8. PubMed ID: 22653969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
    Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
    Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.
    Barker HE; Patel R; McLaughlin M; Schick U; Zaidi S; Nutting CM; Newbold KL; Bhide S; Harrington KJ
    Mol Cancer Ther; 2016 Sep; 15(9):2042-54. PubMed ID: 27422809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
    Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
    Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
    Parsels LA; Qian Y; Tanska DM; Gross M; Zhao L; Hassan MC; Arumugarajah S; Parsels JD; Hylander-Gans L; Simeone DM; Morosini D; Brown JL; Zabludoff SD; Maybaum J; Lawrence TS; Morgan MA
    Clin Cancer Res; 2011 Jun; 17(11):3706-15. PubMed ID: 21482692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
    Sakurikar N; Thompson R; Montano R; Eastman A
    Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
    Xiao Z; Xue J; Sowin TJ; Zhang H
    Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
    King C; Diaz HB; McNeely S; Barnard D; Dempsey J; Blosser W; Beckmann R; Barda D; Marshall MS
    Mol Cancer Ther; 2015 Sep; 14(9):2004-13. PubMed ID: 26141948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways.
    Tian H; Faje AT; Lee SL; Jorgensen TJ
    Neoplasia; 2002; 4(2):171-80. PubMed ID: 11896572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA damage by X-rays and their impact on replication processes.
    Parplys AC; Petermann E; Petersen C; Dikomey E; Borgmann K
    Radiother Oncol; 2012 Mar; 102(3):466-71. PubMed ID: 22326574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chk1 is essential for tumor cell viability following activation of the replication checkpoint.
    Cho SH; Toouli CD; Fujii GH; Crain C; Parry D
    Cell Cycle; 2005 Jan; 4(1):131-9. PubMed ID: 15539958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.